<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1224">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04341207</url>
  </required_header>
  <id_info>
    <org_study_id>2020-001250-21</org_study_id>
    <secondary_id>2020/3078</secondary_id>
    <nct_id>NCT04341207</nct_id>
  </id_info>
  <brief_title>Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients</brief_title>
  <acronym>ONCOVID</acronym>
  <official_title>COVID 19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease Upon Hydroxychloroquine and Azithromycin Therapy in French Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients (Part
      A).

      To evaluate the Covid-19 disease-specific mortality rate in cancer patients treated by
      hydroxychloroquine and azithromycin (Part B).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients</measure>
    <time_frame>Up to 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Cancer &amp; COVID 19</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advanced Cancer Patients with SARS-CoV-2 positive test &amp; Covid19 symptoms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Advanced Cancer Patients with SARS-CoV-2 negative test &amp; Covid19 symptoms. Patients with a chest CT-scan compatible with Covid19 disease shall be treated in part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Advanced Cancer Patients with SARS-CoV-2 positive or negative test &amp; no Covid19 symptoms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advanced Cancer Patients with SARS-CoV-2 positive test AND chest CT-scan compatible with Covid19 disease &amp; no Covid19 symptoms &amp; Pretreated or with frail conditions following the HCSP definition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine 200 mg 3 times a day for 10 days</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin 500 mg on day 1 followed by 250 mg/day for 4 days</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All types of locally advanced and metastatic malignancy

          -  Male/female participants

          -  Age&gt;18 y.o.

          -  Signed informed consent for participation in the study

          -  No restriction on Eastern Cooperative Oncology Group (ECOG)/World Health Organization
             (WHO) Performance Status

          -  Subject should not have received a prior systemic anti-viral treatment for Covid19
             disease.

        Exclusion Criteria:

          -  Patients with known hypersensitivity to hydroxychloroquine or chloroquine,
             azithromycin, erythromycin, or any other macrolide, ketolide or any of the excipients
             of the hydroxychloroquine and/or azithromycin-based specialty used.

          -  Severe hepatic impairment and patients with severe cholestasis.

          -  Patients with renal insufficiency with creatinine clearance &lt; 40 mL/min.

          -  Combinations of drugs contraindicated in accordance with the approvals of the
             specialties used.

          -  Patients currently treated with Tamoxifen

          -  Patients already treated by hydroxychloroquine or azithromycin for Covid19 disease or
             currently treated with other antiviral drugs against coronavirus.

          -  Patients with known contra-indication to treatment with the study drug, including
             retinopathy, G6PD deficiency, QT prolongation and severe hepato-cellular
             insufficiency.

          -  Patients post allogeneic hematopoietic stem cell transplantation are eligible to the
             Part B treatments but the potential toxic effects of hydroxychloroquin and
             azithromycin on hematopoietic stem cells should be taken into consideration by
             prescribers.

          -  Pregnant or breastfeeding women. Women of childbearing potential (WOCBP, as defined in
             appendix 2) should have a negative urine or serum pregnancy test within 72 hours prior
             to receiving the first dose of study medication. If the urine test is positive or
             cannot be confirmed as negative, a serum pregnancy test will be required.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lisa DEROSA, MD</last_name>
    <phone>0142114211</phone>
    <phone_ext>+33</phone_ext>
    <email>lisa.derosa@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan MICHIELS, MD</last_name>
    <phone>0142114211</phone>
    <phone_ext>+33</phone_ext>
    <email>Stefan.michiels@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa DEROSA, MD</last_name>
      <phone>0142114211</phone>
      <phone_ext>+33</phone_ext>
      <email>lisa.derosa@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Stefan MICHIELS, MD</last_name>
      <phone>0142114211</phone>
      <phone_ext>+33</phone_ext>
      <email>stefan.michiels@gustaveroussy.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

